Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology — MIBI-THYR  

Malignancy of Thyroid Nodules Clinical Trial

Official title: Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology

Status Recruiting

Clinical Trial Summary

The main objective of the study is to show that the addition of ultrasonography to the dual tracer scintigraphy MIBI-Tc99m/Iodine-123 will increase (at least +5%) the negative predictive value compared to the dual tracer scintigraphy alone in detection of malignancy in thyroid nodules ≥15 mm classified as Bethesda III-IV on cytology.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Malignancy of Thyroid Nodules
• Neoplasms
• Thyroid Diseases
• Thyroid Nodule

• NCT number: NCT03498183
• Study type: Interventional
• Source: Nantes University Hospital
• Contact: Eric Mirallié, MD
• Phone: 02.40.08.49.78
• Email: eric/mirallie@chu-nantes.fr
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: January 17, 2019
• Completion date: July 1, 2021